Connecting via Winsock to STN

10/049,164

Welcome to STN International! Enter x:x

LOGINID:[redacted]

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	5	AUG 11	STN AnaVist workshops to be held in North America
NEWS	6	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	7	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	8	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:31:37 ON 19 SEP 2005

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:31:45 ON 19 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9
DICTIONARY FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10049164.str



chain nodes :
17 18
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 15 16
chain bonds :
11-12 15-18 16-17
ring bonds :
1-2 1-6 2-3 2-11 3-4 3-9 4-5 5-6 9-10 10-11 12-13 12-16 13-14 14-15 15-16
exact/norm bonds :
1-2 1-6 2-3 2-11 3-4 3-9 4-5 5-6 9-10 10-11 11-12 12-13 12-16 13-14 14-15 15-16 15-18 16-17
isolated ring systems :
containing 1 : 12 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:32:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3216 TO ITERATE

62.2% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 60919 TO 67721
PROJECTED ANSWERS: 54755 TO 61213

L2 50 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:32:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65169 TO ITERATE

100.0% PROCESSED 65169 ITERATIONS 58171 ANSWERS
SEARCH TIME: 00.00.01

L3 58171 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 15:32:23 ON 19 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Sep 2005 VOL 143 ISS 13
FILE LAST UPDATED: 18 Sep 2005 (20050918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4       207164 L3

=> s l4 and fluorescen? probe
         405555 FLUORESCEN?
         213499 PROBE
         107218 PROBES
         283011 PROBE
                (PROBE OR PROBES)
          12819 FLUORESCEN? PROBE
                (FLUORESCEN?(W)PROBE)
L5          484 L4 AND FLUORESCEN? PROBE

=> s l5 and activity(W)based
        2058993 ACTIVITY
         404479 ACTIVITIES
        2226737 ACTIVITY
                (ACTIVITY OR ACTIVITIES)
        1798409 BASED
           1648 ACTIVITY(W)BASED
L6            2 L5 AND ACTIVITY(W)BASED

=> d l6 ibib abs hitstr tot

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2002:899767  CAPLUS
DOCUMENT NUMBER:         138:250529
TITLE:                   Trifunctional chemical probes for the consolidated
                         detection and identification of enzyme activities from
                         complex proteomes
AUTHOR(S):               Adam, Gregory C.; Sorensen, Erik J.; Cravatt, Benjamin
                         F.
CORPORATE SOURCE:        The Skaggs Institute for Chemical Biology and the
                         Department of Chemistry, The Scripps Research
                         Institute, La Jolla, CA, 92037, USA
SOURCE:                  Molecular and Cellular Proteomics (2002), 1(10),
                         828-835
                         CODEN: MCPOBS; ISSN: 1535-9476
PUBLISHER:               American Society for Biochemistry and Molecular
```

Biology, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:250529

AB Chemical probes that covalently modify the active sites of enzymes in complex proteomes are useful tools for identifying enzyme activities associated with discrete (patho)physiol. states. Researchers in proteomics typically use two types of **activity-based** probes to fulfill complementary objectives: **fluorescent probes** for rapid and sensitive target detection and biotinylated probes for target purification and identification. Accordingly, we hypothesized that a strategy in which the target detection and target isolation steps of **activity-based** proteomic expts. were merged might accelerate the characterization of differentially expressed protein activities. Here we report the synthesis and application of trifunctional chemical proteomic probes in which elements for both target detection (e.g. rhodamine) and isolation (e.g. biotin) are appended to a sulfonate ester reactive group, permitting the consolidated visualization and affinity purification of labeled proteins by a combination of in-gel fluorescence and avidin chromatog. procedures. A trifunctional Ph sulfonate probe was used to identify several tech. challenging protein targets, including the integral membrane enzyme 3β-hydroxysteroid dehydrogenase/Δ5-isomerase and the cofactor-dependent enzymes platelet-type phosphofructokinase and type II tissue transglutaminase. The latter two enzyme activities were significantly up-regulated in the invasive estrogen receptor-neg. (ER(-)) human breast cancer cell line MDA-MB-231 relative to the non-invasive ER(+) breast cancer lines MCF7 and T-47D. Collectively these studies demonstrate that chemical proteomic probes incorporating elements for both target detection and target isolation fortify the important link between the visualization of differentially expressed enzyme activities and their subsequent mol. identification, thereby augmenting the information content achieved in **activity-based** profiling expts.

IT **56-65-5**, 5'-ATP, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(labeling of platelet-type phosphofructokinase by trifunctional Ph sulfonate probe is inhibited by ATP)

RN 56-65-5 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:615942 CAPLUS
DOCUMENT NUMBER: 137:165832
TITLE: **Activity based** probe analysis
INVENTOR(S): Patricelli, Matthew P.
PATENT ASSIGNEE(S): Activx Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002063271	A2	20020815	WO 2002-US3808	20020205
WO 2002063271	C1	20021024		
WO 2002063271	A3	20030710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1364209	A2	20031126	EP 2002-714857	20020205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003175986	A1	20030918	US 2002-49164	20021021

PRIORITY APPLN. INFO.:	US 2001-266687P	P	20010205
	US 2001-339424P	P	20011211
	WO 2002-US3808	W	20020205

OTHER SOURCE(S): MARPAT 137:165832

AB The invention concerns methods and compns. are described for analyzing complex protein mixts. using fluorescent **activity-based** probes. In particular, probes that specifically react with and bind to the active form of one or more target proteins are employed. Fluorescent signals obtained from the labeled active target proteins can be related to the presence or amount of active members of the desired target protein class. The methods and compns. described herein can be used, for example, to provide diagnostic information concerning pathogenic states, in identifying proteins that may act as therapeutic targets, and in drug discovery.

IT **446850-50-6P 446850-53-9P 446850-55-1DP,**
reaction with rhodamine green **446850-58-4P 446850-61-9P**
446850-64-2P 446850-67-5P 446850-69-7DP,
reaction with rhodamine green **446850-71-1P 446850-73-3P**
446850-76-6P 446850-79-9P 446850-81-3P
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(**activity based** probe anal.)

RN 446850-50-6 CAPLUS

CN Adenosine, 5'-deoxy-5'-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2'(or 3')-[(2-aminoethyl)carbamate] (9CI) (CA INDEX NAME)

CM 1

CRN 446850-49-3
CMF C15 H22 N6 O5

Absolute stereochemistry.



CM 2

CRN 109-58-0
CMF C3 H8 N2 O2



RN 446850-53-9 CAPLUS
CN Adenosine, 5'-amino-5'-deoxy-, monoester with 9-[2-carboxy-4(or 5)-[[[2-(carboxyamino)ethyl]amino]carbonyl]phenyl]-3,6-bis(dimethylamino)xanthylium inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 2

CRN 14365-44-7
CMF C10 H14 N6 O3

Absolute stereochemistry.



RN 446850-55-1 CAPLUS
CN Adenosine, 5'-amino-5'-deoxy-, 2'(or 3')-[(2-aminoethyl)carbamate] (9CI) (CA INDEX NAME)

CM 1

CRN 14365-44-7
CMF C10 H14 N6 O3

Absolute stereochemistry.



CM 2

CRN 109-58-0
CMF C3 H8 N2 O2



RN 446850-58-4 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[4-(fluorosulfonyl)benzoyl]amino]-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-57-3
CMF C17 H17 F N6 O6 S

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-61-9 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[4-(ethenylsulfonyl)benzoyl]amino]-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-60-8
CMF C19 H20 N6 O6 S

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-64-2 CAPLUS
CN Adenosine, 5'-deoxy-5'-[(1-oxo-2-propenyl)amino]-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-63-1
CMF C13 H16 N6 O4

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-67-5 CAPLUS
CN Adenosine, 5'-[(2-chloro-1-oxo-2-propenyl)amino]-5'-deoxy-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-66-4
CMF C13 H15 Cl N6 O4

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-69-7 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[4-(fluorosulfonyl)benzoyl]amino]-, 2'(or 3')-[(2-aminoethyl)carbamate] (9CI) (CA INDEX NAME)

CM 1

CRN 446850-57-3
CMF C17 H17 F N6 O6 S

Absolute stereochemistry.



CM 2

CRN 109-58-0
CMF C3 H8 N2 O2



RN 446850-71-1 CAPLUS
CN Adenosine, 5'-O-[(4-methoxyphenyl)diphenylmethyl]-, 2'(or 3')-[(2-aminoethyl)carbamate] (9CI) (CA INDEX NAME)

CM 1

CRN 51600-11-4
CMF C30 H29 N5 O5

Absolute stereochemistry.



CM 2

CRN 109-58-0
CMF C3 H8 N2 O2

$H_2N-CH_2-CH_2-NH-CO_2H$

RN 446850-73-3 CAPLUS
CN Adenosine, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 2

CRN 58-61-7
CMF C10 H13 N5 O4

Absolute stereochemistry.



RN 446850-76-6 CAPLUS
CN Adenosine, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate] 5'-(chloroacetate), inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-75-5
CMF C12 H14 Cl N5 O5

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-79-9 CAPLUS
CN Adenosine, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-

4(or 3)-carboxybenzoyl]amino]ethyl]carbamate] 5'-[4-(fluorosulfonyl)benzoate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 2

CRN 57454-44-1
CMF C17 H16 F N5 O7 S

Absolute stereochemistry.



RN 446850-81-3 CAPLUS
CN Adenosine, 5'-amino-5'-deoxy-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 446850-53-9
CMF C38 H40 N10 O8
CCI IDS

CM 3

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 4

CRN 14365-44-7
CMF C10 H14 N6 O3

Absolute stereochemistry.



=> s l5 and tag
20980 TAG
8077 TAGS

```
        24726 TAG
              (TAG OR TAGS)
L7          2 L5 AND TAG

=> l7 not l6
L7 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l7 not l6
L8          2 L7 NOT L6

=> dup rem l6 l7
PROCESSING COMPLETED FOR L6
PROCESSING COMPLETED FOR L7
L9          4 DUP REM L6 L7 (0 DUPLICATES REMOVED)
              ANSWERS '1-4' FROM FILE CAPLUS

=> d l7 ibib abs hitstr tot

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2003:871776  CAPLUS
DOCUMENT NUMBER:         141:49860
TITLE:                   Molecular Properties of Purified Human Uncoupling
                         Protein 2 Refolded from Bacterial Inclusion Bodies
AUTHOR(S):               Jekabsons, Mika B.; Echtay, Karim S.; Arechaga,
                         Ignacio; Brand, Martin D.
CORPORATE SOURCE:        Dunn Human Nutrition Unit, Medical Research Council,
                         Cambridge, CB2 2XY, UK
SOURCE:                  Journal of Bioenergetics and Biomembranes (2003),
                         35(5), 409-418
                         CODEN: JBBID4; ISSN: 0145-479X
PUBLISHER:               Kluwer Academic/Plenum Publishers
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   One way to study low-abundance mammalian mitochondrial carriers is by
     ectopically expressing them as bacterial inclusion bodies.  Problems
     encountered with this approach include protein refolding, homogeneity, and
     stability.  In this study, we investigated protein refolding and
     homogeneity properties of inclusion body human uncoupling protein 2
     (UCP2).  N-methylanthraniloyl-tagged ATP (Mant-ATP) expts. indicated two
     independent inclusion body UCP2 binding sites with dissociation consts. (Kd)
     of 0.3-0.5 and 23-92 μM. Dimethylanthranilate, the fluorescent
     tag without nucleotide, bound with a Kd of greater than 100 μM,
     suggesting that the low affinity site reflected binding of the tag
     .  By direct titration, UCP2 bound [8-14C] ATP and [8-14C] ADP with Kds of
     4-5 and 16-18 μM, resp.  Mg2+ (2 mM) reduced the apparent ATP affinity
     to 53 μM, an effect entirely explained by chelation of ATP; with Mg2+,
     Kd using calculated free ATP was 3 μM. A combination of gel filtration,
     Cu2+-phenanthroline crosslinking, and ultracentrifugation indicated that
     75-80% of UCP2 was in a monodisperse, 197 kDa form while the remainder was
     aggregated.  We conclude that (a) Mant-tagged nucleotides are useful
     fluorescent probes with isolated UCP2 when used with
     dimethylanthranilate controls; (b) UCP2 binds Mg2+-free nucleotides: the
     Kd for ATP is about 3-5 μM and for Mant-ATP it is about 10 times lower;
     and (c) in C12E9 detergent, the monodisperse protein may be in dimeric
     form.
IT   56-65-5, 5'-ATP, biological studies 58-64-0, 5'-ADP,
     biological studies
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (FRET fluorescence of N-methylanthraniloyl-tagged ATP as method of
        assessing nucleotide binding to purified human uncoupling protein 2
```

using dimethylanthranilate controls)
RN 56-65-5 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-64-0 CAPLUS
CN Adenosine 5'-(trihydrogen diphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **85287-56-5**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(FRET fluorescence of N-methylanthraniloyl-tagged ATP as method of assessing nucleotide binding to purified human uncoupling protein 2 using dimethylanthranilate controls)
RN 85287-56-5 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 3'-[2-(methylamino)benzoate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:90063 CAPLUS
DOCUMENT NUMBER: 136:163716
TITLE: Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
INVENTOR(S): Hahn, Klaus M.; Toutchkine, Alexei; Muthyala, Rajeev; Kraynov, Vadim; Bark, Steven J.; Burton, Dennis R.; Chamberlain, Chester
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008245	A2	20020131	WO 2001-US22194	20010713
WO 2002008245	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2002028890	A1	20020411	WO 2000-US26821	20000929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002055133	A1	20020509	US 2001-839577	20010420
CA 2415960	AA	20020131	CA 2001-2415960	20010713
EP 1301473	A2	20030416	EP 2001-954689	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004067537	A1	20040408	US 2003-455713	20030603
PRIORITY APPLN. INFO.:			US 2000-218113P	P 20000713
			WO 2000-US26821	W 20000929
			US 2001-279302P	P 20010328
			US 2001-839577	A 20010420
			WO 2001-US22194	W 20010713

OTHER SOURCE(S): MARPAT 136:163716

AB The invention provides peptide synthons having protected functional groups for attachment of desired moieties (e.g. functional mols. or probes). Also provided are peptide conjugates prepared from such synthons, and synthon and conjugate preparation methods including procedures for identifying optimum probe attachment sites. Biosensors are provided having functional mols. that can locate and bind to specific biomols. within living cells. Biosensors can detect chemical and physiol. changes in those biomols. as living cells are moving, metabolizing and reacting to its environment. Methods are included for detecting GTP activation of a Rho GTPase protein using polypeptide biosensors. When the biosensor binds GTP-activated Rho

GTPase protein, an environmentally sensitive dye emits a signal of a different lifetime, intensity or wavelength than when not bound. New fluorophores whose fluorescence responds to environmental changes are also provided that have improved detection and attachment properties, and that can be used in living cells, or in vitro.

IT **56-65-5**, ATP, biological studies **86-01-1**, GTP
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(labeled peptides, proteins and antibodies and processes and intermediates useful for preparation)

RN 56-65-5 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 86-01-1 CAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




```
=> s l4 and tag
         20980 TAG
          8077 TAGS
         24726 TAG
                 (TAG OR TAGS)
L10        372 L4 AND TAG

=> l10 and protein
L10 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l10 and protein
       1785091 PROTEIN
       1243217 PROTEINS
       2074982 PROTEIN
```

```
                (PROTEIN OR PROTEINS)
L11        304 L10 AND PROTEIN

=> s l11 and conjugate
          61979 CONJUGATE
          54913 CONJUGATES
          95734 CONJUGATE
                (CONJUGATE OR CONJUGATES)
L12         27 L11 AND CONJUGATE

=> s l12 and label
          58073 LABEL
          19704 LABELS
          69584 LABEL
                (LABEL OR LABELS)
L13          4 L12 AND LABEL

=> s l13 not l9
L14          2 S L9
L15          2 S L9
L16          4 L13 NOT (L14 OR L15)

=> d l13 ibib abs hitstr tot

L13  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:1037349  CAPLUS
DOCUMENT NUMBER:          142:19000
TITLE:                    Labeling of fusion proteins by enzymic
                          incorporation of a coenzyme A derivative into an acyl
                          carrier protein moiety
INVENTOR(S):              Johnsson, Kai; George, Nathalie
PATENT ASSIGNEE(S):       EPFL-Ecole Polytechnique Federale de Lausanne, Switz.
SOURCE:                   PCT Int. Appl., 46 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004104588         A1    20041202    WO 2004-IB1733           20040519
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRIORITY APPLN. INFO.:                        EP 2003-405364      A  20030523
OTHER SOURCE(S):          MARPAT 142:19000
AB   A method for labeling acyl carrier protein (ACP) fusion
     proteins using derivs. of CoA is described. The method relies on
     the transfer of a label from a CoA type substrate to an ACP
     fusion protein using a holo-acyl carrier protein
     synthase (ACPS) or a homolog thereof. The method allows detecting and
     manipulating the fusion protein, both in vitro and in vivo, by
     attaching mols. to the fusion proteins that introduce a new
     phys. or chemical property to the fusion protein. Examples of such
```

labels are, among others, spectroscopic probes or reporter mols., affinity **tags**, mols. generating reactive radicals, cross-linkers, ligands mediating **protein-protein** interactions or mols. suitable for the immobilization of the fusion **protein**. Synthesis of a series of reporter mol. **conjugates**, including digoxigenin, Cy3 and Cy5, with CoA is reported.

IT **85-61-0D**, Coenzyme A, derivs.
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(labeling of acyl carrier **protein** with; labeling of fusion **proteins** by enzymic incorporation of coenzyme derivative into acyl carrier **protein** moiety)

RN 85-61-0 CAPLUS

CN Coenzyme A (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **756898-07-4P 756898-08-5P 756898-09-6P 756898-10-9P**
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and labeling use of; labeling of fusion **proteins** by enzymic incorporation of coenzyme derivative into acyl carrier **protein** moiety)

RN 756898-07-4 CAPLUS

CN Coenzyme A, S-[1-[6-[2-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]hydrazino]-6-oxohexyl]-2,5-dioxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 756898-08-5 CAPLUS

CN Coenzyme A, S-[1-[6-[2-[4-[[(3β,5β,12β,14β)-21,23-epoxy-12,14-dihydroxy-23-oxo-24-norchol-20(22)-en-3-yl]amino]-1,4-dioxobutyl]hydrazino]-6-oxohexyl]-2,5-dioxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 756898-09-6 CAPLUS

CN Coenzyme A, S-[1-[2-[[6-[2-[3-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-5-sulfo-3H-indolio]-1-oxohexyl]amino]ethyl]-2,5-dioxo-3-pyrrolidinyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 756898-10-9 CAPLUS
CN Coenzyme A, S-[1-[2-[[6-[2-[5-(1-ethyl-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene)-1,3-pentadienyl]-3,3-dimethyl-5-sulfo-3H-indolio]-1-oxohexyl]amino]ethyl]-2,5-dioxo-3-pyrrolidinyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:350520 CAPLUS
DOCUMENT NUMBER: 141:119215
TITLE: Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A
AUTHOR(S): Yates, Susan P.; Merrill, Allan R.
CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry and Biochemistry, Department of Chemistry and Biochemistry, University of Guelph, Guelph, ON, N1G 2W1, Can.
SOURCE: Biochemical Journal (2004), 379(3), 563-572
CODEN: BIJOAK; ISSN: 0264-6021
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pseudomonas aeruginosa produces the virulence factor, ETA (exotoxin A),

which catalyzes an ADP-ribosyltransferase reaction of its target **protein**, eEF2 (eukaryotic elongation factor-2). Currently, this **protein-protein** interaction is poorly characterized and this study was aimed at identifying the contact sites between eEF2 and the catalytic domain of ETA (PE24H, an ETA from P. aeruginosa, a 24 kDa C-terminal fragment containing a His6 **tag**). Single-cysteine residues were introduced into the toxin at 21 defined surface-exposed sites and labeled with the fluorophore, IAEDANS [5-(2-iodoacetylaminoethylamino)-1-naphthalenesulfonic acid]. Fluorescence quenching studies using acrylamide, and fluorescence lifetime and wavelength emission maxima analyses were conducted in the presence and absence of eEF2. Large changes in the microenvironment of the AEDANS [5-(2-aminoethylamino)-1-naphthalenesulfonic acid] probe after eEF2 binding were not observed as dictated by both fluorescence lifetime and wavelength emission maxima values. This supported the proposed minimal contact model, which suggests that only small, discrete contacts occur between these **proteins**. As dictated by the bimol. quenching constant (kq) for acrylamide, binding of eEF2 with toxin caused the greatest change in acrylamide accessibility (>50%) when the fluorescence **label** was near the active site or was located within a known catalytic loop. All mutant **proteins** showed a decrease in accessibility to acrylamide once eEF2 bound, although the relative change varied for each labeled **protein**. From these data, a low-resolution model of the toxin-eEF2 complex was constructed based on the minimal contact model with the intention of enhancing our knowledge on the mode of inactivation of the ribosome translocase by the Pseudomonas toxin.

IT **53-84-9**, NAD
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(substrate, binding; eukaryotic elongation factor-2 (eEF2) interaction with ADP-ribosyltransferase domain of Pseudomonas exotoxin A elucidated using site-specific fluorophore labeled exotoxin A mutants)

RN 53-84-9 CAPLUS

CN Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:472604 CAPLUS

DOCUMENT NUMBER: 139:49507

TITLE: Synthesis and use of affinity probes directed toward adenine nucleotide-binding **proteins**

INVENTOR(S): Campbell, David A.; Wash, Paul

PATENT ASSIGNEE(S): Activx Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050248	A2	20030619	WO 2002-US39073	20021205
WO 2003050248	A3	20040122		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003134303	A1	20030717	US 2002-213359	20020805
PRIORITY APPLN. INFO.:			US 2001-339424P	P 20011211
			US 2002-213359	A 20020805

AB The invention relates to compns. and methods for the synthesis and use of adenosine nucleotide-binding **protein**-directed affinity **labels**. Adenosine nucleotide-binding **proteins** may be labeled with probes comprising adenosine, or an analog thereof, functionalized at the 5' position with reactive group capable of reacting with an amino acid side chain functionality at an adenosine nucleotide binding site, and at the 2' or 3' position with a **tag** for sequestering and/or identifying the resulting **conjugate**. In particular, one such probe is 5'-fluorosulfonylbenzoylamido-2'(3')-(2-TAMRA-amidoethylcarbamoyl)adenosine, shown to effectively **label** EGF receptor tyrosine kinase in A431 cells and insulin receptor kinase in boiled rat liver lysate. The probes may be used for determining the presence or amount of one or more adenosine nucleotide-binding **proteins** in a complex mixture, particularly a cellular mixture, for screening for drugs, and other purposes associated with the presence of the adenine nucleotide-binding **protein**(s) in a cell or changes in the presence, amount, activity, or relative concentration of the active adenosine nucleotide-binding **protein**.

IT **446850-58-4P 446850-61-9P 446850-64-2P 446850-79-9P 545400-02-0P 545400-03-1P**
RL: BUU (Biological use, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and use of affinity probes directed toward adenine nucleotide-binding **proteins**)

RN 446850-58-4 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[4-(fluorosulfonyl)benzoyl]amino]-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-57-3
CMF C17 H17 F N6 O6 S

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-61-9 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[4-(ethenylsulfonyl)benzoyl]amino]-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-60-8
CMF C19 H20 N6 O6 S

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-64-2 CAPLUS
CN Adenosine, 5'-deoxy-5'-[(1-oxo-2-propenyl)amino]-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-63-1
CMF C13 H16 N6 O4

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 446850-79-9 CAPLUS
CN Adenosine, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate] 5'-[4-(fluorosulfonyl)benzoate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 2

CRN 57454-44-1
CMF C17 H16 F N5 O7 S

Absolute stereochemistry.



RN 545400-02-0 CAPLUS
CN Adenosine, 5'-[(chloroacetyl)amino]-5'-deoxy-, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 545400-01-9
CMF C12 H15 Cl N6 O4

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 545400-03-1 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[4-(fluorosulfonyl)benzoyl]amino]-, 2'(or 3')-[[2-[[3(or 4)-carboxy-4(or 3)-(3,6-diaminoxanthylium-9-yl)benzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 545399-99-3
CMF C24 H20 N4 O6
CCI IDS





CM 2

CRN 446850-57-3
CMF C17 H17 F N6 O6 S

Absolute stereochemistry.



IT **14365-44-7 51600-11-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and use of affinity probes directed toward adenine nucleotide-binding **proteins**)
RN 14365-44-7 CAPLUS
CN Adenosine, 5'-amino-5'-deoxy- (6CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51600-11-4 CAPLUS
CN Adenosine, 5'-O-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **446850-50-6P 446850-53-9P 446850-71-1P**
446850-73-3P 446850-76-6P 545400-00-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and use of affinity probes directed toward adenine nucleotide-binding **proteins**)
RN 446850-50-6 CAPLUS
CN Adenosine, 5'-deoxy-5'-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2'(or 3')-[(2-aminoethyl)carbamate] (9CI) (CA INDEX NAME)

CM 1

CRN 446850-49-3
CMF C15 H22 N6 O5

Absolute stereochemistry.



CM 2

CRN 109-58-0

CMF C3 H8 N2 O2



RN 446850-53-9 CAPLUS
CN Adenosine, 5'-amino-5'-deoxy-, monoester with 9-[2-carboxy-4(or 5)-[[[2-(carboxyamino)ethyl]amino]carbonyl]phenyl]-3,6-bis(dimethylamino)xanthylium inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 2

CRN 14365-44-7
CMF C10 H14 N6 O3

Absolute stereochemistry.



RN 446850-71-1 CAPLUS
CN Adenosine, 5'-O-[(4-methoxyphenyl)diphenylmethyl]-, 2'(or 3')-[(2-aminoethyl)carbamate] (9CI) (CA INDEX NAME)

CM 1

CRN 51600-11-4
CMF C30 H29 N5 O5

Absolute stereochemistry.



CM 2

CRN 109-58-0
CMF C3 H8 N2 O2

$H_2N-CH_2-CH_2-NH-CO_2H$

RN 446850-73-3 CAPLUS
CN Adenosine, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





CM 2

CRN 58-61-7
CMF C10 H13 N5 O4

Absolute stereochemistry.



RN 446850-76-6 CAPLUS
CN Adenosine, 2'(or 3')-[[2-[[3(or 4)-[3,6-bis(dimethylamino)xanthylium-9-yl]-4(or 3)-carboxybenzoyl]amino]ethyl]carbamate] 5'-(chloroacetate), inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 446850-75-5
CMF C12 H14 Cl N5 O5

Absolute stereochemistry.



CM 2

CRN 446850-52-8
CMF C28 H28 N4 O6
CCI IDS





RN 545400-00-8 CAPLUS
CN Adenosine, 5'-amino-5'-deoxy-, 2'(or 3')-[[2-[[3(or 4)-carboxy-4(or

3)-(3,6-diaminoxanthylium-9-yl)benzoyl]amino]ethyl]carbamate], inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 545399-99-3
CMF C24 H20 N4 O6
CCI IDS





CM 2

CRN 14365-44-7
CMF C10 H14 N6 O3

Absolute stereochemistry.



L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:284222 CAPLUS
DOCUMENT NUMBER: 134:307611
TITLE: Conjugated polymer **tag** complexes and their preparation and use in assays
INVENTOR(S): Leif, Robert C.; Franson, Richard C.; Vallarino, Lidia
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001027625 A1 20010419 WO 2000-US27787 20001007
W: CA, CH, DE, FI, GB, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2387380 AA 20010419 CA 2000-2387380 20001007
EP 1221052 A1 20020710 EP 2000-968871 20001007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY
PRIORITY APPLN. INFO.: US 1999-158718P P 19991008
WO 2000-US27787 W 20001007

AB Processes are described for: (1) the sequential solid phase synthesis of polymers with at least one **tag**, which can be a light emitting and/or absorbing mol. species (optical-**label**), a paramagnetic or radioactive **label**, or a **tag** that permits the phys. separation of particles including cells. When multiple optical-**labels** are suitably arranged in three-dimensional space, the energy transfer from one mol. species to another can be maximized and the radiationless loss between members of the same mol. species can be minimized; (2) the coupling of these polymers to biol. active and/or biol. compatible mols. through peripheral pendant substituents having at least one reactive site; and (3) the specific cleavage of the coupled polymer from a solid phase support. The tagged-peptide or polymers produced by these processes and their **conjugates** with an analyte-binding species, such as a monoclonal antibody or a polynucleotide probe are described. When functionalized europium macrocyclic complexes, as taught in our U.S. patents 5,373,093 and 5,696,240, are bound to polylysine and other peptides, the emitted light increases linearly with the amount of bound macrocyclic complex. Similar linearity will also result for multiple luminescent macrocyclic complexes of other lanthanide ions, such as samarium, terbium, and dysprosium, when they are bound to a polymer or mol.

IT **56-65-5**, analysis **58-61-7**, Adenosine, analysis **58-64-0**, Adenosine 5'-(trihydrogen diphosphate), analysis **61-19-8**, 5'-Adenylic acid, analysis **85-32-5**, 5'-Guanylic acid **86-01-1 118-00-3**, Guanosine, analysis **146-91-8**, Guanosine 5'-(trihydrogen diphosphate)
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(conjugated polymer **tag** complexes and preparation and use in assays)

RN 56-65-5 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-61-7 CAPLUS
CN Adenosine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-64-0 CAPLUS
CN Adenosine 5'-(trihydrogen diphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 61-19-8 CAPLUS
CN 5'-Adenylic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85-32-5 CAPLUS
CN 5'-Guanylic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 86-01-1 CAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 118-00-3 CAPLUS
CN Guanosine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 146-91-8 CAPLUS
CN Guanosine 5'-(trihydrogen diphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.88	228.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -5.84 -5.84

STN INTERNATIONAL LOGOFF AT 15:45:58 ON 19 SEP 2005